Global Opioid-Induced Constipation Market Spotlight Report 2019: Shionogi Leads the Industry Sponsors with the Highest Number of Clinical Trials, Followed by Pfizer – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Opioid-Induced Constipation” report has been added
to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Opioid-Induced Constipation
market, comprising key marketed and pipeline drugs, clinical trials,
upcoming and regulatory events, patent information, probability of
success, epidemiology data, and licensing and acquisition deals, as well
as presenting drug-specific revenue forecasts

Key Takeaways

• The approved drugs in the opioid-induced constipation (OIC) space
  predominantly target opioid receptors, with the exception of Amitiza,
  a type-2 chloride channel activator. All of the marketed drugs are
  administered via the oral route, with one product also being available
  in a subcutaneous formulation.
• The majority of industry-sponsored drugs in active clinical
  development for OIC are in Phase II, with only one drug in Phase III.
  Therapies in mid-to-late-stage development for OIC target opioid
  receptors and guanylyl cyclase c receptor. These therapies are
  administered via the oral route.
• The overall likelihood of approval of a Phase I gastroenterology (non
  inflammatory bowel disease)-other asset is 22.5%, and the average
  probability a drug advances from Phase III is 66.7%. Drugs, on
  average, take 10.1 years from Phase I to approval, compared to 9.9
  years in the overall gastroenterology (non inflammatory bowel disease)
  space.
• The clinical trials distribution across Phase I-IV indicates that the
  majority of trials for OIC have been in the late phases of
  development, with 61% in Phase III-IV, and only 39% in Phase I-II.
• Clinical trial activity in the OIC space is dominated by completed
  trials. Shionogi has the highest number of completed trials for OIC,
  with nine trials.
• Shionogi leads the industry sponsors with the highest number of
  clinical trials for OIC, followed by Pfizer

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Management of OIC with laxatives

Management of OIC with opioid antagonists

Management of OIC with Amitiza, a secretagogue chloride channel activator

EPIDEMIOLOGY

Recent prevalence studies

Challenges

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations

CHMP Delays Review of Portola’s Ondexxya; Who Will Pass Muster?

PROBABILITY OF SUCCESS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

For more information about this report visit https://www.researchandmarkets.com/r/enlsp3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]

For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related
Topics: Gastroenterology